Particle Technology for Dry Powder Inhalers hosted by NCSU BMIG
Name:
Particle Technology for Dry Powder Inhalers hosted by NCSU BMIG
Date:
October 6, 2023
Time:
10:40 AM - 11:30 AM EDT
Website:
go.ncsu.edu/btec_seminar
Event Description:
Dry powder inhaler products deliver drugs that are central to pulmonary disease treatment, notably asthma, chronic obstructive pulmonary and infectious diseases. Drug particle size and morphology is critical to effective aerosol generation and lung deposition where specific receptors involved in broncho-motor tone or the underlying cause of disease, inflammation are targeted. Milling and spray drying are the most frequently employed techniques for the production of respirable particles. Each offers advantages for particular applications. The benefits of specific methods of manufacture of dry powders and combination with inhaler devices will be presented in the context of critical performance characteristics to support disease therapy.
Dr. Hickey is Distinguished Fellow, at RTI International, Professor Emeritus of Pharmacoengineering and Molecular Pharmaceutics of the Eshelman School of Pharmacy, and Adjunct Professor of Biomedical Engineering of the School of Medicine at the University of North Carolina at Chapel Hill. He is a Fellow of the American Association for the Advancement of Science, the American Association of Pharmaceutical Scientists, the Royal Society of Biology, the Royal Society of Medicine and the National Academy of Inventors. He received the Research Achievement Award of the Particulate Presentations and Design Division of the Powder Technology Society of Japan, the David W Grant Award in Physical Pharmacy of the American Association of Pharmaceutical Scientists; Thomas T Mercer Joint Prize for Excellence in Inhaled Medicines and Pharmaceutical Aerosols of the American Association for Aerosol Research and the International Society for Aerosols in Medicine, the Ralph Shangraw Memorial Award for Excipient and Excipient Technology of the International Pharmaceutical Excipient Consortium Foundation.
Dr. Hickey is founder (and formerly President and CEO) of Cirrus Pharmaceuticals, Inc.; founder (formerly CSO) of Oriel Therapeutics, Inc,; CEO of Astartein, LLC. and; Scientific Advisor to TFF Pharmaceuticals Inc.; Chair of the USP Joint Sub-Committee on Nanotechnology, Member of the USP Pharmaceutical Dosage Forms Expert Committee (DFEC) and Aerosols Sub-Committee of the DFEC of the United States Pharmacopeia. He conducts multidisciplinary research programs in the field of pulmonary drug and vaccine delivery for the treatment and prevention of a variety of diseases.
Dr. Hickey is Distinguished Fellow, at RTI International, Professor Emeritus of Pharmacoengineering and Molecular Pharmaceutics of the Eshelman School of Pharmacy, and Adjunct Professor of Biomedical Engineering of the School of Medicine at the University of North Carolina at Chapel Hill. He is a Fellow of the American Association for the Advancement of Science, the American Association of Pharmaceutical Scientists, the Royal Society of Biology, the Royal Society of Medicine and the National Academy of Inventors. He received the Research Achievement Award of the Particulate Presentations and Design Division of the Powder Technology Society of Japan, the David W Grant Award in Physical Pharmacy of the American Association of Pharmaceutical Scientists; Thomas T Mercer Joint Prize for Excellence in Inhaled Medicines and Pharmaceutical Aerosols of the American Association for Aerosol Research and the International Society for Aerosols in Medicine, the Ralph Shangraw Memorial Award for Excipient and Excipient Technology of the International Pharmaceutical Excipient Consortium Foundation.
Dr. Hickey is founder (and formerly President and CEO) of Cirrus Pharmaceuticals, Inc.; founder (formerly CSO) of Oriel Therapeutics, Inc,; CEO of Astartein, LLC. and; Scientific Advisor to TFF Pharmaceuticals Inc.; Chair of the USP Joint Sub-Committee on Nanotechnology, Member of the USP Pharmaceutical Dosage Forms Expert Committee (DFEC) and Aerosols Sub-Committee of the DFEC of the United States Pharmacopeia. He conducts multidisciplinary research programs in the field of pulmonary drug and vaccine delivery for the treatment and prevention of a variety of diseases.
